Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

12 May 2020

CDMO says it has made "notable changes" to its supply chain processes to ensure continuing supply of medicines during COVID-19 pandemic

Recipharm has increased stocks of active pharmaceutical ingredients (APIs) and raw materials to ensure continuity of supply and to meet higher antibiotics demand amid the global coronavirus pandemic, the Swedish contract development and manufacturing organisation said on Tuesday.

Recipharm increases API and raw material stocks to ensure supply amid higher antibiotics demand

Antibiotics demand has risen as secondary bacterial infections are common in severely ill patients with COVID-19.

“We are increasing the safety stock of both APIs and raw material and are looking at different shift patterns for the existing team, as well as recruiting more personnel where required,” said Erik Haeffler, Vice President, Manufacturing Services & Head of Sustainability, at Recipharm.

The company has also seen generally higher demand for goods and services to support the fight against COVID-19.

“Naturally, this has put a strain on our supply chain and has affected it in various, but manageable, ways,” he said, adding that the company had made "notable changes" to its supply chain processes to maintain the supply of critical medicines.

Recipharm manufactures antibiotics – which can only be manufactured in dedicated plants with the correct technology and capabilities -- at four of its facilities.

“We are following the government guidelines and implementing the appropriate safety measures to ensure we continue to work efficiently,” Haeffler said.

Delays in both incoming materials and the shipment of its goods have been recent challenges for the company, with suppliers at reduced capacity, and tighter border control restrictions slowing down the transportation of goods.

Despite these issues, Recipharm said it had adjusted well to this “difficult and testing situation” to minimize the impact on the supply chain.

Recipharm added it may already have reached peak demand and predicted that volumes will return to ‘normal’ once the acute state of COVID-19 has passed.

Last week, Recipharm said it had secured supply of the API chloroquine phosphate for its drug Klorokinfosfat RPH Pharma and started manufacturing the product. While chloroquine products are not currently indicated for treatment or prevention of COVID-19, some clinical studies involving chloroquine and hydroxychloroquine have recently been initiated.

Read More

Related news

Can the industry really claim it's 'business as usual'?

Can the industry really claim it's 'business as usual'?

19 May 2020

ChargePoint Technology's Chief Commercial Officer says "yes" it can.

Read more 
HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

Samsung Biologics expands business continuity excellence with additional ISO 22301 certification

19 May 2020

The certification is expected to instill greater 'supply' trust with clients, particularly during the current pandemic.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Pharmapack expert recommends holistic approach to sustainability

Pharmapack expert recommends holistic approach to sustainability

18 May 2020

Although the industry might be 30% along its sustainability journey, greater interoperability is needed from materials to devices.

Read more 
KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

KND Labs earns Active Pharmaceutical Ingredients certification for CBD ingredients

12 May 2020

Company's manufacturing methods and processes reviewed by an independent third-party auditor to ensure the products have the highest-quality ingredients possible.

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Demand for immunity products to be sustained long-term says SIRIO

Demand for immunity products to be sustained long-term says SIRIO

11 May 2020

Movement towards healthy lifestyles and preventative supplements the lasting behavioural change post COVID-19.

Read more 
AbbVie completes Allergan acquisition

AbbVie completes Allergan acquisition

11 May 2020

Creates biopharmaceutical company with leadership positions in immunology, hematologic oncology, neuroscience, and Allergan aesthetics.

Read more